AccessPak for HIV PEP Expanded with Kaletra and Intelence

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Ask your doctor before using ritonavir together with etravirine, this may decrease the effects of etravirine. Contact your doctor if your condition changes. If your doctor does prescribe these medications together, you may need a dose adjustment or special test to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

GENERALLY AVOID: Coadministration with full-dose ritonavir (600 mg twice a day) may significantly decrease the plasma concentrations of etravirine. The mechanism of interaction has not been described but may involve ritonavir induction of CYP450 2C19 and 2C9, of which etravirine is a substrate. In 11 study subjects administered etravirine with ritonavir 600 mg twice a day, etravirine peak plasma concentration (Cmax) decreased by 32% and systemic exposure (AUC) decreased by 46%.

MANAGEMENT: Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, the use of etravirine in combination with full-dose ritonavir should be avoided. Etravirine may be used with low-dose ritonavir administered as a pharmacokinetic booster in certain protease inhibitor regimens.

AccessPak for HIV PEP Expanded with Kaletra

Generic Name: emtricitabine / lopinavir / ritonavir / tenofovir

Brand name: AccessPak for HIV PEP Expanded with Kaletra

Synonyms: n.a.

What is AccessPak for HIV PEP Expanded with Kaletra?

Intelence

Generic Name: etravirine

Brand name: Intelence

Synonyms: n.a.

What is Intelence?